Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Keiichi Fujiwara et al.|The Lancet Oncology|2021Cited by 401
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Justin P.O. Lindemann et al.|Cancer Discovery|2020Cited by 134
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Dominique Berton et al.|JAMA Network Open|2023Cited by 120
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J. Davis, Janice M. Mehnert, Juan Martín-Liberal et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 93
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90